Getting the steroid as an injection rather than a tablet halved the odds of still taking it a year later

Steroids in early rheumatoid arthritis are supposed to be scaffolding. They hold the joints quiet for a few months while the drugs that actually change the disease get going, and then they come down.

A great many of them never come down. Writing in Annals of the Rheumatic Diseases, researchers followed 2,222 patients with newly diagnosed disease and found that a year later, 47% of those who had been given steroids by mouth were still taking them.

Among those given the same drug by injection, the figure was 26%.

What the two routes actually are

Corticosteroids are similar to hormones that your adrenal glands make to fight stress associated with illnesses and injuries, and they reduce inflammation and affect the immune system. The molecule is not what differs here. The delivery is.

An oral steroid is a daily tablet. Somebody has to decide to reduce it, write a taper, and follow it through, and the patient has to tolerate feeling worse on the way down. It is a decision that has to be made repeatedly and can be deferred indefinitely.

An injection, into a joint or a muscle, is a single event. It wears off. Stopping requires nobody to do anything.

The numbers

During the first 3 months, 1,661 patients received no glucocorticoid, 421 oral, 121 parenteral, and 19 both.

At twelve months, the pattern was stark. Advanced therapies and steroid use, respectively at 12 months, were 7% and 8% with no steroid, 14% and 47% after oral, 14% and 26% after injection, and 16% and 63% after both.

Set against never having started, the odds of being on steroids at one year was 9.8 for oral and 4.1 for parenteral. Both routes leave people on the drug far more often than not starting does. One leaves them there twice as often as the other.

Why staying on matters

There is no cure for rheumatoid arthritis, but early treatment can help you manage symptoms, reduce joint damage, and lead a productive life.

Steroids are very good at the first part of that sentence and contribute nothing to the second. What they do contribute, over years, is a well-catalogued list: bone loss and fractures, raised blood sugar, cataracts, skin that tears, infections that arrive more easily, and an adrenal system that stops making its own cortisol.

None of that is controversial, and none of it is why people stay on the drug. They stay on it because it works, because stopping feels worse before it feels better, and because there is always a reason to postpone the taper by another month.

The comparison this study cannot make

Nobody was randomized. Rheumatologists chose the route, and they chose it for reasons.

A patient with one furiously inflamed knee gets an injection into that knee. A patient with pain in every joint of both hands gets tablets. Those two people were always going to have different twelve-month trajectories, and no amount of adjustment recovers the reason a clinician reached for one option over the other.

That confounding runs in a specific direction here: injections likely went to people with more localized, less severe disease, who would have been easier to get off steroids by any route.

What survives the caveat

One comparison is harder to explain away. Rates of advanced therapy use were similar between groups, both at 14%.

If the injected patients simply had milder disease, you would expect fewer of them to need escalation to biologic drugs over the year. They did not differ. The two groups ended up at the same place on disease control and at different places on steroid dependence, which is at least consistent with the route mattering.

The authors put it as a possibility rather than a finding: parenteral administration may facilitate earlier discontinuation of steroids.

The number nobody comments on

Three quarters of these patients got no steroid at all in their first three months, and that group did best on everything.

That is not evidence that steroids are unnecessary; those patients were presumably the ones whose disease did not demand it. But it is a useful corrective to the impression that early rheumatoid arthritis routinely means a course of prednisolone. Most of this cohort managed without.

For anyone starting treatment, the transferable question is not which route to request. It is when the steroid is supposed to stop, and who is going to make sure it does.